Why this ASX healthcare stock is a top rebound candidate with big upside 

ASX healthcare stocks have faced significant headwinds over the last 12 months. 

However, this has created a value opportunity for several healthcare companies. 

One in particular that is drawing positive attention from brokers is Sonic Healthcare Ltd (ASX: SHL). 

It is the largest private medical laboratory and pathology services operator in Australia, the United Kingdom, Germany, and Switzerland.

It is also a major provider of diagnostic imaging in Australia and is the largest medical centre operator in the country.

After falling 18% over the last 12 months, a new report from Bell Potter suggests this ASX healthcare stock could rebound significantly in the near future. 

FY26 Results Preview

The team at Bell Potter provided an outlook on what investors can expect from the company's upcoming FY26 results. 

Bell Potter estimates revenue +0.6%, EBITDA +1.5%, and NPAT +0.7% to be slightly ahead of consensus.

Bell Potter argues that pathology is increasingly a scale game. If lower fees force weaker operators out or accelerate industry consolidation, Sonic Healthcare could potentially gain market share and offset some of the fee pressure through greater efficiency.

The new CEO has now been in the role for six months, so investors will want a clearer strategy and outlook. Bell Potter sees potential for positive guidance/upgrades if several areas improve:

• Margin benefits from the Swiss and German acquisitions
• Continued strength in the UK, particularly more NHS outsourcing wins
• Improvement in the US business following its operational review

Given the new CEO has had over six months in the role, the FY26 result offers an opportunity to address several issues and set a clear direction for investors.

Big upside for ASX healthcare stock 

Based on this guidance, the team at Bell Potter have retained their buy recommendation for this ASX healthcare stock. 

The broker also has a price target of $28.75 on Sonic Healthcare shares, which indicates an upside potential of over 27%. 

SHL is trading close to decade lows on an EV/EBITDA basis and is relatively well priced against its domestic large cap healthcare peers, with a FY27e PE of c.16x being amongst the lowest in the peer group.

We would expect that should the recent recovery in large cap healthcare valuations continue, it would be a tailwind for SHL, particularly if it can impress in the forthcoming business update and the CEO impresses investors, despite being early in his tenure.

The post Why this ASX healthcare stock is a top rebound candidate with big upside  appeared first on The Motley Fool Australia.

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026